Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension

Hypertension

Volumn 60, Issue 2, 2012, Pages 419-424

  Mahfoud, Felix ^a   Cremers, Bodo ^a   Janker, Julia ^a   Link, Britta ^a   Vonend, Oliver ^b   Ukena, Christian ^a   Linz, Dominik ^a   Schmieder, Roland ^c   Rump, Lars Christian ^b   Kindermann, Ingrid ^a   Sobotka, Paul Andrew ^d   Krum, Henry ^e   Scheller, Bruno ^a   Schlaich, Markus ^f   Laufs, Ulrich ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d OHIO STATE UNIVERSITY   (United States)

^e MONASH UNIVERSITY   (Australia)

^f Baker Heart and Diabetes Research Center   (Australia)

Author keywords

microalbuminuria; renal function; renal resistive index; renal sympathetic denervation; therapy resistant hypertension; urinary albumin excretion

Indexed keywords

ALBUMIN; CYSTATIN C;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY FUNCTION; MACROALBUMINURIA; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PULSE PRESSURE; RATING SCALE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ALBUMINURIA; BLOOD PRESSURE; CATHETERS; CYSTATIN C; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84864282373     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.193870     Document Type: Article

References (33)

1. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J. 2011;32:1599-1604.
2. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (keep) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008; 51:S30-S37. (Pubitemid 351444715)
3. Heine GH, Reichart B, Ulrich C, Kohler H, Girndt M. Do ultrasound renal resistance indices reflect systemic rather than renal vascular damage in chronic kidney disease? Nephrol Dial Transplant. 2007;22:163-170. (Pubitemid 46050341)
4. Momen A, Bower D, Leuenberger UA, Boehmer J, Lerner S, Alfrey EJ, Handly B, Sinoway LI. Renal vascular response to static handgrip exercise: sympathetic vs. autoregulatory control. Am J Physiol Heart Circ Physiol. 2005;289:H1770-H1776. (Pubitemid 41369023)
5. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Leoncini G, Ruello N, Zagami P, Bezante GP, Derchi LE, Deferrari G. Increased renal resistive index in patients with essential hypertension: A marker of target organ damage. Nephrol Dial Transplant. 1999;14: 360-365. (Pubitemid 29062791)
6. Gross ML, Amann K. Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens. 2004;13: 307-312. (Pubitemid 38582303)
7. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-939.
8. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100: 1049-1057.
9. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010;376:1903-1909.
10. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373:1275-1281.
11. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209-215.
12. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
13. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation. 2011;123: 1940-1946.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
15. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol. 2006;17: 2120-2126. (Pubitemid 44141901)
16. Chobanian AV, Bakris GL, Black HK, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
17. International Expert Committee report on the role of the a1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-1334.
18. Mancini M, Daniele S, Raffio T, Liuzzi R, Sabbatini M, Cianciaruso B, Ferrara LA, Salvatore M. Intra and interobserver variability of renal allograft ultrasound volume and resistive index measurements. Radiol Med. 2005;109:385-394. (Pubitemid 43942441)
19. Mostbeck GH, Kain R, Mallek R, Derfler K, Walter R, Havelec L, Tscholakoff D. Duplex Doppler sonography in renal parenchymal disease: histopathologic correlation. J Ultrasound Med. 1991;10:189-194.
20. Veglio F, Frascisco M, Melchio R, Provera E, Rabbia F, Oliva S, Chiandussi L. Assessment of renal resistance index after captopril test by Doppler in essential and renovascular hypertension. Kidney Int. 1995;48: 1611-1616.
21. Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, Ponte L, Calvi C, Repetto M, Robaudo C, Maiello M. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia. 1998;41:121-124. (Pubitemid 28105752)
22. Leoncini G, Martinoli C, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Derchi LE, Deferrari G, Pontremoli R. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine gits. Nephron. 2002;90:169-173. (Pubitemid 34701992)
23. Taniwaki H, Ishimura E, Kawagishi T, Matsumoto N, Hosoi M, Emoto M, Shoji T, Shoji S, Nakatani T, Inaba M, Nishizawa Y. Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: A duplex Doppler sonography study. Diabetes Care. 2003;26:132-137. (Pubitemid 36929005)
24. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency: The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med. 1996;334:939-945. (Pubitemid 26114159)
25. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Böhm M. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011; 58:1176-1182.
26. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002; 105:1354-1359. (Pubitemid 34260428)
27. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846-851.
28. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1717. (Pubitemid 37076355)
29. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11:1469-1478. (Pubitemid 30483463)
30. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
31. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011;22:1353-1364.
32. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension. 2011;58:e19.
33. Krum H, Barman N, Schlaich M, Sobotka PA, Esler M, Mahfoud F, Böhm M, Dunlap M. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.